Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents

Baseline tumour burden is a prognostic factor for patients with melanoma and non–small-cell lung cancer treated with immunotherapy. However, no data are available on its role in other solid tumours, nor for treatment with next-generation immunoncology agents (NGIOs). We reviewed data of patients wit...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2020-11, Vol.139, p.92-98
Main Authors: Tarantino, Paolo, Marra, Antonio, Gandini, Sara, Minotti, Marta, Pricolo, Paola, Signorelli, Giulia, Criscitiello, Carmen, Locatelli, Marzia, Belli, Carmen, Bellomi, Massimo, Curigliano, Giuseppe
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological - therapeutic use
Baseline tumour size
Cancer
Clinical trials
Continuity (mathematics)
Female
Humans
Immune checkpoint inhibitors
Immunotherapy
Immunotherapy - methods
Lesions
Lung cancer
Male
Mathematical analysis
Melanoma
Middle Aged
Multivariate analysis
Neoplasms - immunology
Neoplasms - therapy
Next-generation immunoncology agents
Non-small cell lung carcinoma
Phase 1 trials
Progression-Free Survival
Quartiles
Response Evaluation Criteria in Solid Tumors
Solid tumors
Survival
Total tumour burden
Treatment Outcome
Tumor Burden - drug effects
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Baseline tumour burden is a prognostic factor for patients with melanoma and non–small-cell lung cancer treated with immunotherapy. However, no data are available on its role in other solid tumours, nor for treatment with next-generation immunoncology agents (NGIOs). We reviewed data of patients with any solid tumour consecutively treated at our institution from August 2014 to March 2019, who received ≥1 dose of immune checkpoint inhibitor and/or NGIO within phase 1 trials. Baseline tumour burden was calculated as ∑i Response Evaluation Criteria in Solid Tumours 1.1 baseline target lesions (baseline tumour size [BTS]) or as sum of all measurable baseline lesions (total tumour burden [TTB]); the impact of both parameters on treatment outcomes was investigated. One hundred fifty patients were included in the analysis. Median BTS and TTB were 79 mm and 212 mm, respectively. Objective response rate was found significantly associated with BTS (p 
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2020.08.026